Unlike traditional culture or serological testing, rapid testing for Legionella pneumophila can influence point-of-care treatment decisions and thus enable early appropriate therapy of patients
The QuickStripe™ Legionella pneumophila is an in vitro diagnostic test based on immunochromatographic assay. It is designed for detection of soluble antigen from Legionella pneumophila serogroup 1 in human urine specimen.
Community-acquired pneumonia (CAP) the most common type of pneumonia, is a leading cause of illness and death worldwide. Legionella pneumophila is increasingly recognized as a cause of sporadic and epidemic CAP in all age groups and affects both healthy and immunosuppressed individuals. L. pneumophila accounts for 2–9% of cases of CAP. Despite the development of a range of clinical guidelines for the management of CAP, a significant clinical and economic burden remains, especially in adults ≥65 years old.
A large proportion of patients with CAP are now commonly treated with broad-spectrum empiric antibiotic therapy as per guideline recommendations. There are however, concerns that the overprescribing of broad-spectrum antibiotics may increase the risk of superinfection by antibiotic-resistant bacteria or Clostridium difficile. Accurate diagnosis using a urine antigen tests for Legionella pneumophila would enable the use of targeted antibiotic therapy with narrow-spectrum antibiotics being the agents of choice.
QuickStripe™ Legionella pneumophila test benefits:
|Catalog No||Product name||Tests/kit||Approvals|
|41225||QuickStripe™ Legionella pneumophila||20||CE|